·
Shenzhen, China and San Diego, USA – December 29, 2025 – SeekIn Inc. today reported a landmark year highlighted by six peer‑reviewed publications, two major international conference presentations, rapid overseas expansion, new trademark protections in the United States, and growing clinical recognition in China.
Breakthrough publications
- A two-step MCED strategy combining an affordable first‑line OncoSeek test with a more comprehensive SeekInCare assay was published in Cancer Research Communications and further detailed in company communications, demonstrating substantial reductions in false positives and screening costs while maintaining strong clinical performance.
- Multiple clinical studies of SeekInCare in both retrospective and real‑world prospective cohorts confirmed its ability to detect over 20 cancer types with high specificity and sensitivity comparable to leading multi‑cancer early detection tests, culminating in publication in the Journal of Molecular Diagnostics.
- LungCanSeek, a novel four‑protein, AI‑driven lung cancer blood test, was reported in Translational Lung Cancer Research to offer accurate and cost‑effective early detection suitable for large‑scale use, including in low‑ and middle‑income countries.
- OncoSeek data from five independent cohorts of roughly 15,000 participants across multiple countries validated its low‑cost, multi‑cancer detection performance and tissue‑of‑origin prediction using widely available protein platforms.
- A prospective study published in BMC Cancer demonstrated that SeekInClarity, a CE‑IVD–marked, blood-based multi‑omics assay that generates a molecular tumor burden score, can non‑invasively monitor treatment response and independently predict progression‑free and overall survival in lymphoma patients beyond interim PET/CT and conventional biomarkers.
- LeukoPrint molecular karyotyping kit obtained CE marking in Europe and demonstrated value for copy‑number–based genomic profiling in hematologic malignancies, improving diagnostic yield and risk stratification when combined with conventional cytogenetics in publication in Blood Advances.
- Collectively, these six publications spanning two‑step MCED, SeekInCare, SeekInClarity, LungCanSeek, OncoSeek, and LeukoPrint underscore SeekIn’s multi‑omics strategy for pan‑cancer early detection, disease characterization, and hematologic cancer management.
International presentations
- At the Early Detection of Cancer Conference (EDCC) in Portland, SeekIn presented large multicohort OncoSeek data emphasizing equitable cancer detection in diverse populations and highlighting the suitability of low‑cost protein‑based MCED for low‑ and middle‑income regions.
- Additional two‑step MCED and lung cancer early detection results were showcased at major international meetings, with the EDCC and CNAPS (the 14th International Symposium on Circulating Nucleic Acids in Plasma & Serum in Hong Kong) forums providing global visibility for the company’s approach to balancing accuracy, cost, and accessibility.
Global expansion and trademarks
- SeekIn advanced overseas commercialization by partnering to introduce its tests into emerging markets including Pakistan, Colombia, and El Salvador, supporting national and regional efforts to modernize cancer screening infrastructure.
- The company continued to build a durable intellectual‑property and brand foundation, including registration and active use of its core trademarks such as SeekInCare, OncoSeek, LeukoPrint, and related marks in the United States, European Union and Mexico as part of a broader global trademark strategy.
Expert recognition in China
- In China, SeekIn’s technologies contributed to expert consensus efforts on blood‑based multi‑cancer early detection and molecular diagnostics, with large domestic validation cohorts for OncoSeek and SeekInCare supporting integration of liquid biopsy into national screening and diagnostic paradigms.
- The accumulation of local clinical evidence and endorsement by leading oncology and hematology centers strengthened the company’s position as a trusted innovator in China’s rapidly evolving precision oncology ecosystem.